CXCR4 and neoplasm: Mice treated with AMD3100 or the combination of AMD3100 and cisplatin had significantly lower bioluminescence from CXCR4-CBRN and Ar-CBC complementation relative to overall tumor burden, showing that this drug successfully blocks CXCR4 signaling in ovarian cancer cells in vivo (p<0.01).